Disc Medicine annual r&d spending
2020
2021
2022
2023
2024
2025
Disc Medicine R&D Spending Growth & History (IRON)
Disc Medicine's r&d spending was $170.6M for fiscal 2025.
View full Disc Medicine company overviewDisc Medicine annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $170.6M | $74.0M | +76.52% |
| 2024 | 2024-12-31 | $96.7M | $27.4M | +39.57% |
| 2023 | 2023-12-31 | $69.3M | $35.8M | +107.15% |
| 2022 | 2022-12-31 | $33.4M | $8.3M | +32.84% |
| 2021 | 2021-12-31 | $25.2M | −$3.0M | −10.65% |
| 2020 | 2020-12-31 | $28.2M | — | — |
Disc Medicine quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.9M | $614,000 | +1.33% |
| Q1 2026 | 2026-03-31 | $45.9M | $18.1M | +65.34% |
| Q4 2025 | 2025-12-31 | $46.2M | $21.4M | +86.41% |
| Q3 2025 | 2025-09-30 | $50.3M | $25.6M | +103.91% |
| Q2 2025 | 2025-06-30 | $46.3M | $22.8M | +97.23% |
| Q1 2025 | 2025-03-31 | $27.8M | $4.1M | +17.12% |
| Q4 2024 | 2024-12-31 | $24.8M | $2.2M | +9.89% |
| Q3 2024 | 2024-09-30 | $24.7M | $10.3M | +71.20% |
| Q2 2024 | 2024-06-30 | $23.5M | $11.4M | +94.09% |
| Q1 2024 | 2024-03-31 | $23.7M | $3.5M | +17.46% |
| Q4 2023 | 2023-12-31 | $22.6M | $12.5M | +125.29% |
| Q3 2023 | 2023-09-30 | $14.4M | $6.5M | +82.84% |
| Q2 2023 | 2023-06-30 | $12.1M | $4.4M | +56.86% |
| Q1 2023 | 2023-03-31 | $20.2M | $12.4M | +158.02% |
| Q4 2022 | 2022-12-31 | $10.0M | — | — |
| Q3 2022 | 2022-09-30 | $7.9M | −$5.6M | −41.39% |
| Q2 2022 | 2022-06-30 | $7.7M | −$3.1M | −28.85% |
| Q1 2022 | 2022-03-31 | $7.8M | −$4.0M | −33.64% |
| Q3 2021 | 2021-09-30 | $13.5M | $6.7M | +100.01% |
| Q2 2021 | 2021-06-30 | $10.8M | $5.3M | +96.13% |
| Q1 2021 | 2021-03-31 | $11.8M | $3.6M | +43.43% |
| Q4 2020 | 2020-12-31 | $7.7M | — | — |
| Q3 2020 | 2020-09-30 | $6.7M | — | — |
| Q2 2020 | 2020-06-30 | $5.5M | — | — |
| Q1 2020 | 2020-03-31 | $8.2M | — | — |
Disc Medicine r&d spending trends
Over the last five fiscal years, Disc Medicine's r&d spending increased from $28.2M to $170.6M, a change of $142.5M. The latest reported quarter, Q2 2026, shows $46.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Disc Medicine source filings ↗